Cognito Therapeutics, a neurotechnology company specializing in the development of disease-modifying therapies for neurodegenerative diseases, has announced the enrollment of the first participant in a biomarker substudy within the HOPE pivotal trial. This trial is designed to evaluate a novel disease-modifying therapy that induces gamma frequency brain activity through non-invasive sensory stimulation, potentially slowing the progression of Alzheimer's Disease in a home-based setting.

Cognito Therapeutics, expressed excitement about reaching a significant clinical milestone with the enrollment of the first participant in the HOPE biomarker substudy. He emphasized the company's progress, with over 240 participants currently involved in the study across 60 active sites in the United States. Dr. Kern underscored their commitment to meeting study completion timelines and the potential approval of a groundbreaking non-pharmacologic therapy for Alzheimer's Disease.

The therapy's focus is on promoting gamma frequency brain activity, crucial for maintaining the structural integrity and function of the brain. In Alzheimer's Disease, the failure to preserve neuronal, synaptic, and myelin structures can impact cognitive functions. The HOPE biomarker substudy will assess MRI, cerebrospinal fluid, and plasma biomarkers, providing valuable insights into AD progression. This approach may enable early identification of responses to Cognito therapy and help identify patients and disease areas most responsive to treatment.

Cognito Therapeutics, highlighted the company's unique approach compared to experimental drugs targeting amyloid plaques and tau tangles. Cognito's non-invasive medical device addresses abnormal electrical activities in the brain, offering a potential alternative treatment for Alzheimer's Disease.

Recent results from Cognito's Phase 2 OVERTURE study, published in the Journal of Alzheimer's Disease, demonstrated that their gamma sensory stimulation reduced white matter atrophy and preserved brain myelin content in patients with mild-moderate AD. The open-label extension study reported consistent disease modification effects, including reduced brain atrophy and improved ADCS-ADL scores over 18 months, with no observed safety concerns.

The OVERTURE study provided real-time evidence of brain target modulation through EEG and illustrated the biological mechanism of action through MRI brain imaging. Cognito Therapeutics is actively advancing its innovative approach, providing hope for a new treatment option for Alzheimer's Disease.

 Alzheimer's Disease is a complex neurodegenerative condition affecting synaptic and neuronal activity, with Cognito Therapeutics aiming to address additional factors beyond amyloid plaques and tau tangles in their pursuit of an effective treatment.

 

Source: businesswire.com

Report Abuse